...
search icon
gtbp-img

GT Biopharma Inc Share Price

GTBP
NAQ
$0.4636
-$0.01
(-2.12%)
1D
Industry: Biotechnology Sector: Health Care

GT Biopharma Inc Analyst Forecast

GT Biopharma Inc Share Price Chart

GT Biopharma Inc Key Stock Metrics

Market Cap info-icon
This is a company’s total value as determined by the stock market. It is calculated by multiplying the total number of a company's outstanding shares by the current market price of one share.
$12.54M
P/E Ratio info-icon
This is the ratio of a security’s current share price to its earnings per share. This ratio determines the relative value of a company’s share.
0
Volume info-icon
This is the total number of shares traded during the most recent trading day.
605.75K
Avg Volume info-icon
This is the average number of shares traded during the most recent 30 days.
0
Dividend Yield info-icon
This ratio shows how much income you earn in dividend payouts per year for every dollar invested in the stock (or the stock’s annual dividend payment expressed as a percentage of its current price).
0.00%
Beta info-icon
This measures the expected move in a stock’s price relative to movements in the overall market. The market, such as the S&P 500 Index, has a beta of 1.0. If a stock has a Beta greater (or lower) than 1.0, it suggests that the stock is more (or less) volatile than the broader market.
1.25
52-week Range info-icon
This shows the range of the stock’s price between the 52-week high (the highest price of the stock for the past 52 weeks) and the 52-week low (the lowest price of the stock for the past 52 weeks).
$0.4 L
$3.85 H
$0.4636

About GT Biopharma Inc, Common Stock

GT Biopharma, Inc., a clinical stage biopharmaceutical company, engages in the development and commercialization of immuno-oncology products based on its proprietary Tri-specific Killer Engager (TriKE) and Tetra-specific Killer Engager (Dual Targeting TriKE) fusion protein immune cell engager technology platforms. It develops GTB-3650, which is in preclinical studies that target CD33 on the surface of myeloid leukemias and an agonistic camelid; GTB-5550 that targets B7-H3 on the surface of advanced solid tumors; and GTB-7550, a product candidate in development for the treatment of lupus and other autoimmune disorders. The company was formerly known as OXIS International, Inc. and changed its name to GT Biopharma, Inc. in July 2017. GT Biopharma, Inc. was incorporated in 1965 and is based in San Francisco, California. more

Industry: BiotechnologySector: Health Care

GT Biopharma Inc Stock Returns

Time FrameGTBPSectorS&P500
1-Week Return-13.99%-1.08%-1.38%
1-Month Return-32.32%-0.47%-1.81%
3-Month Return-36.49%2.13%1.38%
6-Month Return-72.4%17.04%5.68%
1-Year Return-79.3%6.56%11.74%
3-Year Return-98.1%16.78%65.15%
5-Year Return-99.76%34.34%73.68%
10-Year Return-70.68%137.88%260.03%

GT Biopharma Inc Financials

Dec '20Dec '21Dec '22Dec '23Dec '245YR TREND
Total Revenue-----[{"date":"2020-12-31","value":"-","profit":true},{"date":"2021-12-31","value":"-","profit":true},{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":"-","profit":true},{"date":"2024-12-31","value":"-","profit":true}]
Cost of Revenue-----[{"date":"2020-12-31","value":"-","profit":true},{"date":"2021-12-31","value":"-","profit":true},{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":"-","profit":true},{"date":"2024-12-31","value":"-","profit":true}]
Gross Profit-----[{"date":"2020-12-31","value":"-","profit":true},{"date":"2021-12-31","value":"-","profit":true},{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":"-","profit":true},{"date":"2024-12-31","value":"-","profit":true}]
Gross Margin-----[{"date":"2020-12-31","value":"-","profit":true},{"date":"2021-12-31","value":"-","profit":true},{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":"-","profit":true},{"date":"2024-12-31","value":"-","profit":true}]
Operating Expenses6.76M57.52M21.26M13.58M14.36M[{"date":"2020-12-31","value":11.76,"profit":true},{"date":"2021-12-31","value":100,"profit":true},{"date":"2022-12-31","value":36.96,"profit":true},{"date":"2023-12-31","value":23.6,"profit":true},{"date":"2024-12-31","value":24.97,"profit":true}]
Operating Income(6.76M)(57.52M)(21.26M)(13.58M)(14.36M)[{"date":"2020-12-31","value":-676400000,"profit":false},{"date":"2021-12-31","value":-5751500000,"profit":false},{"date":"2022-12-31","value":-2125700000,"profit":false},{"date":"2023-12-31","value":-1357600000,"profit":false},{"date":"2024-12-31","value":-1436400000,"profit":false}]
Total Non-Operating Income/Expense(24.85M)(1.18M)657.00K6.50M1.60M[{"date":"2020-12-31","value":-382.4,"profit":false},{"date":"2021-12-31","value":-18.13,"profit":false},{"date":"2022-12-31","value":10.11,"profit":true},{"date":"2023-12-31","value":100,"profit":true},{"date":"2024-12-31","value":24.68,"profit":true}]
Pre-Tax Income(28.30M)(58.01M)(20.88M)(7.60M)(13.16M)[{"date":"2020-12-31","value":-2829600000,"profit":false},{"date":"2021-12-31","value":-5801300000,"profit":false},{"date":"2022-12-31","value":-2088400000,"profit":false},{"date":"2023-12-31","value":-759700000,"profit":false},{"date":"2024-12-31","value":-1316200000,"profit":false}]
Income Taxes3.32M680.00K(381.00K)(13.58K)-[{"date":"2020-12-31","value":100,"profit":true},{"date":"2021-12-31","value":20.48,"profit":true},{"date":"2022-12-31","value":-11.48,"profit":false},{"date":"2023-12-31","value":-0.41,"profit":false},{"date":"2024-12-31","value":"-","profit":true}]
Income After Taxes(31.62M)(58.69M)(20.50M)(7.58M)-[{"date":"2020-12-31","value":-3161600000,"profit":false},{"date":"2021-12-31","value":-5869300000,"profit":false},{"date":"2022-12-31","value":-2050300000,"profit":false},{"date":"2023-12-31","value":-758342400,"profit":false},{"date":"2024-12-31","value":"-","profit":true}]
Income From Continuous Operations(28.30M)(58.01M)(20.88M)(10.22M)(13.16M)[{"date":"2020-12-31","value":-2829600000,"profit":false},{"date":"2021-12-31","value":-5801300000,"profit":false},{"date":"2022-12-31","value":-2088400000,"profit":false},{"date":"2023-12-31","value":-1021900000,"profit":false},{"date":"2024-12-31","value":-1316200000,"profit":false}]
Income From Discontinued Operations-----[{"date":"2020-12-31","value":"-","profit":true},{"date":"2021-12-31","value":"-","profit":true},{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":"-","profit":true},{"date":"2024-12-31","value":"-","profit":true}]
Net Income(28.30M)(58.01M)(20.88M)(7.60M)(13.16M)[{"date":"2020-12-31","value":-2829600000,"profit":false},{"date":"2021-12-31","value":-5801300000,"profit":false},{"date":"2022-12-31","value":-2088400000,"profit":false},{"date":"2023-12-31","value":-759700000,"profit":false},{"date":"2024-12-31","value":-1316200000,"profit":false}]
EPS (Diluted)(3.57)(4.23)(0.67)(2.31)(7.00)[{"date":"2020-12-31","value":-357,"profit":false},{"date":"2021-12-31","value":-423,"profit":false},{"date":"2022-12-31","value":-67,"profit":false},{"date":"2023-12-31","value":-231,"profit":false},{"date":"2024-12-31","value":-699.71,"profit":false}]

GT Biopharma Inc Ratios

GT Biopharma Inc Liquidity Ratios

These ratios help you determine the liquidity of the company. Higher is better.

GTBP
Cash Ratio 1.98
Current Ratio 2.70

GT Biopharma Inc Asset Efficiency Ratios

These ratios help you understand the company's efficiency in using its assets to generate returns. Higher is better. For ROE, average long term is around 14%, less than 10% is poor.

GTBP
ROA (LTM) -119.47%
ROE (LTM) -356.99%

GT Biopharma Inc Liability Ratios

These ratios help you understand the company's liabilities, gauging the riskiness of the investment.

GTBP
Debt Ratio Lower is generally better. Negative is bad. 0.31
Common Equity/Total Assets Higher is better. Lower can suggest investment is riskier. 0.69

GT Biopharma Inc Valuation Ratios

These ratios help you understand the company's valuation. Lower may indicate cheaper stocks.

GTBP
Trailing PE NM
Forward PE NM
P/S (TTM) 0.00
P/B 4.18
Price/FCF NM
EV/R 0.00
EV/Ebitda NM

FAQs

What is GT Biopharma Inc share price today?

GT Biopharma Inc (GTBP) share price today is $0.4636

Can Indians buy GT Biopharma Inc shares?

Yes, Indians can buy shares of GT Biopharma Inc (GTBP) on Vested. To buy

from India, you can open a US Brokerage account on Vested today by clicking on Sign Up or Invest in GTBP stock at the top of this page. The account opening process is completely digital and secure, and takes a few minutes to complete.

Can Fractional shares of GT Biopharma Inc be purchased?

Yes, you can purchase fractional shares of GT Biopharma Inc (GTBP) via the Vested app. You can start investing in GT Biopharma Inc (GTBP) with a minimum investment of $1.

How to invest in GT Biopharma Inc shares from India?

You can invest in shares of GT Biopharma Inc (GTBP) via Vested in three simple steps:

  • Click on Sign Up or Invest in GTBP stock at the top of this page
  • Breeze through our fully digital and secure KYC process and open your US Brokerage account in a few minutes
  • Transfer USD funds to your US Brokerage account and start investing in GT Biopharma Inc shares
What is GT Biopharma Inc 52-week high and low stock price?

The 52-week high price of GT Biopharma Inc (GTBP) is $3.85. The 52-week low price of GT Biopharma Inc (GTBP) is $0.4.

What is GT Biopharma Inc price-to-earnings (P/E) ratio?

The price-to-earnings (P/E) ratio of GT Biopharma Inc (GTBP) is

What is GT Biopharma Inc price-to-book (P/B) ratio?

The price-to-book (P/B) ratio of GT Biopharma Inc (GTBP) is 4.18

What is GT Biopharma Inc dividend yield?

The dividend yield of GT Biopharma Inc (GTBP) is 0.00%

What is the Market Cap of GT Biopharma Inc?

The market capitalization of GT Biopharma Inc (GTBP) is $12.54M

What is GT Biopharma Inc's stock symbol?

The stock symbol (or ticker) of GT Biopharma Inc is GTBP

How Can Investors Use GT Biopharma Inc Share Price Data for Long-Term Investment Decisions?

Consider the share price of GT Biopharma Inc as a long-term story and not a daily point list. The price represents a movement of the stock in both good and bad times when looked at over many years. This assists the investors to know whether GT Biopharma Inc has succeeded to expand steadily and overcome market declines. With this price movement observed and the way the business is progressing, it is easier to make a decision whether the stock is worth having in the long term or not.

How does USD - INR currency movement impact returns from GT Biopharma Inc shares for Indian investors?

When investing in GT Biopharma Inc shares, you are not based in India then your investment is not just based on the stock price. It is also determined by the currency movement of the dollar in relation to the rupee. When you have an appreciation of the GT Biopharma Inc stock and the dollar appreciation is also the same, you gain more in terms of rupees. When the rupee appreciated, it will lower your profits. This currency flow is a silent cause of great contribution to your ultimate returns over many years.

How should investors compare GT Biopharma Inc share price with other stocks in the same sector?

Rather than merely checking the share price of GT Biopharma Inc and comparing it with that of other stocks in the same sector, one can check how robust the business is. Investors tend to compare such aspects as profits, cash generation, and the stability of the revenues of the company. This means that GT Biopharma Inc stock in most cases does not react in the same manner as other companies in the sector due to its brand and services revenue.

Signup to access all features and start your US investing journey!

  • Open your account in minutes
  • Take your portfolio global, starting at just $1
Get started

Add ticker to compare

Scroll to Top